This website is intended for use by residents of Sweden only
About Isofol
Isofol Medical AB (publ) is developing the drug candidate arfolitixorin with the aim of increasing the efficacy of current standard treatments for colorectal cancer and certain other tumor diseases. A Phase III study of arfolitixorin has been completed and the company is now evaluating opportunities to advance the drug candidate toward a marketing authorization application by conducting additional studies and entering potential partnerships. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
Upcoming Events
- March 19, 2024 - March 19, 2024
Investor meeting
Isofol invites to an investor meeting on March 19. The meeting will be held in Gothenburg and can also be followed via webcast. - May 08, 2024 - May 08, 2024
Interim report January-March 2024 - August 21, 2024 - August 21, 2024
Interim report January-June 2024
Media – Lates pressreleases
Isofol invites to investor meeting on March 19
GOTHENBURG, Sweden, March 1, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites investors and shareholders to an investor meeting to present…
Isofol Medical AB (publ) publishes year-end report, January – December 2023
GOTHENBURG, Sweden, February 20, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s year-end report for January – December…
Isofol’s Board of Directors decides to initiate the planning of clinical studies and will announce a strategic development plan on March 19
GOTHENBURG, Sweden, February 14, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), has been engaged in intensive strategy work since the new Board…
INVESTORS – reports, events and presentations
Investor meeting March 19
FOLLOW US
Stay updated on the latest news by
following Isofol on Linkedin.